Comparative Pharmacology
Head-to-head clinical analysis: RAPLON versus RAUWOLFIA SERPENTINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAPLON versus RAUWOLFIA SERPENTINA.
RAPLON vs RAUWOLFIA SERPENTINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.
Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.
0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.
Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours in end-stage renal disease).
Terminal elimination half-life: 40-100 hours (mean ~70 h). Accumulation occurs with chronic dosing; steady-state reached in ~2-3 weeks.
Primarily renal excretion of unchanged drug (approximately 80-90% of administered dose within 24 hours); minor biliary/fecal elimination (less than 10%).
Renal (urinary) elimination of unchanged drug and metabolites: approximately 60-70% as metabolites, <1% unchanged. Fecal excretion: 30-40% via bile.
Category C
Category C
Antihypertensive
Antihypertensive